TUSTIN, Calif., April 25 AMDL, Inc. (Amex: ADL),an international biopharma company with development and manufacture ofproprietary pharmaceutical and diagnostic products in China, announced todaythat a 4th Quarter Update and Year End Report on AMDL has been posted byanalyst Lauren Rudd at (http://www.RuddReport.com). It includes a 12 monthtarget price of $23 and a Buy Recommendation.
The Report highlights AMDL's recent and anticipated company goals andobjectives in regards to DR-70(TM), Human Papilloma Virus (HPV), JadePharmaceutical Inc. 2008 business expansion and JPGreen Health & BeautyClinics. It also covers various Peer Group Comparison & Valuation Analysis andtheir views and opinions on financial performance for FY2008.
The 21-page report goes into significant detail about AMDL's products,particularly AMDL's recent announcement in April 2008 that it has entered intoan exclusive sublicense agreement for a diagnostic product for in-vitrogenotype testing in women with Human Papilloma Virus (HPV), a potentialbillion dollar market.
"AMDL has had another profitable quarter, making it two in a row, a trendwe feel goes a long way towards reaffirming our current projections that bythe end of 2008, revenues from Jade alone will reach or exceed $38 million,"Mr. Rudd writes.
About Jade Pharmaceutical Inc.: Jade has access to the fastest growingpharmaceutical and consumer market in the world: China. AMDL, through itssubsidiary, Jade currently manufactures large volume injectable fluids,tablets and other related products, holding licenses for 133 products. It alsomanufactures 107 generic, over the counter and supplemental pharmaceuticalproducts under certified Chinese Good Manufacturing Practice (CGMP) standards.
About AMDL: More information about AMDL and its products can be obtainedat http://www.amdl.com.
Forward-Looking Statements: This news release contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995. Such statements are subject to certain risks and uncertainties, andactual circumstances, events or results may differ materially from thoseprojected in such forward-looking statements. The Company cautions readers notto place undue reliance on any forward-looking statements. The Company doesnot undertake, and specifically disclaims any obligation, to update or revisesuch statements to reflect new circumstances or unanticipated events as theyoccur.
Disclaimer by Rudd
This disclaimer is an integral part of Rudd's service. Please read itbefore investing in any security on which we report.
Opinions are solely those of the staff of The Rudd Report and are subjectto change without notice. Our reports are for information only and we do notoffer securities or solicit the offer of securities of any company. Ourreports are to inform the public and not to promote any company or itssecurities.
We do not inform any company in advance of the nature or conclusions ofour reports nor can a company change what we write.
In the case of AMDL we received a fee for coverage of the current quarterin the amount of $6,000.
Our reports contain factual statements and opinions. We derive thesefactual statements from sources that we believe are accurate. However, we donot represent that the facts presented are accurate or complete. Furthermore,the information contained in this report may become inaccurate because of thepassage of time and should therefore be read for historical information only.Contact: AMDL, Inc. Mr. Paul Knopick AMDL Investor Relations Direct Line: 949.707.5365 Voice Mail: 714.505.4460
SOURCE AMDL, Inc.